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ABSTRACT
Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated
with an increased risk of lung cancer. However, the mechanisms underlying Cr(VI)induced carcinogenesis remain unclear. MicroRNA-21 (miR-21) is a key regulator of
oncogenic processes. Studies have shown that miR-21 exerts its oncogenic activity
by targeting the tumor suppressor gene programmed cell death 4 (PDCD4). The
present study examined the role of miR-21-PDCD4 signaling in Cr(VI)-induced
cell transformation and tumorigenesis. Results showed that Cr(VI) induces ROS
generation in human bronchial epithelial (BEAS-2B) cells. Chronic exposure to
Cr(VI) is able to cause malignant transformation in BEAS-2B cells. Cr(VI) caused
a significant increase of miR-21 expression associated with an inhibition of PDCD4
expression. Notably, STAT3 transcriptional activation by IL-6 is crucial for the
Cr(VI)-induced miR-21 elevation. Stable knockdown of miR-21 or overexpression of
PDCD4 in BEAS-2B cells significantly reduced the Cr(VI)-induced cell transformation.
Furthermore, the Cr(VI) induced inhibition of PDCD4 suppressed downstream
E-cadherin protein expression, but promoted β-catenin/TCF-dependent transcription
of uPAR and c-Myc. We also found an increased miR-21 level and decreased PDCD4
expression in xenograft tumors generated with chronic Cr(VI)-exposed BEAS-2B
cells. In addition, stable knockdown of miR-21 and overexpression of PDCD4 reduced
the tumorogenicity of chronic Cr(VI)-exposed BEAS-2B cells in nude mice. Taken
together, these results demonstrate that the miR-21-PDCD4 signaling axis plays an
important role in Cr(VI)-induced carcinogenesis.

INTRODUCTION

ore processing [2]. It has been reported that overproduction
of reactive oxygen species (ROS) play a major role in
Cr(VI)-induced carcinogenesis [3]. However, a detailed
molecular mechanism of Cr(VI)–induced malignant
transformation and tumorigenesis remains unknown.
MicroRNAs (miRNAs) are a novel class of
endogenous, small, noncoding RNAs that negatively
regulate approximately 30% of the gene expression by a
site-specific interactions at the 3ʹ-UTR of target-mRNAs,

Hexavalent chromium compounds [Cr(VI)
compounds] have been classified as human carcinogens
by the International Agency for Research on Cancer
(IARC) of the World Health Organization (WHO) based
on epidemiological studies results linking Cr(VI) to
lung cancer [1]. Cr(VI) compounds are widely used in
industries, such as plating, paint, steel, tanning, and chrome
www.impactjournals.com/oncotarget
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causing translational repression or degradation [4, 5].
Among them, miR-21 has emerged as a key onco-miR [6],
since it is consistently overexpressed in a number of human
malignancies [7–10]. Increased expression of miR-21 has
been associated with a variety of processes including in
carcinogenesis, apoptosis resistance, cell proliferation,
tumor progression and chemoresistance [11–14]. A recent
study suggests that NADPH oxidase-derived ROS is
essential for the expression and function of miR-21 [15].
PDCD4 is a novel tumor suppressor reported
to inhibit neoplastic transformation, tumor promotion
and progression [4, 16, 17]. It has been established that
miR-21 directly targets the 3′ UTR region of PDCD4 and
down-regulates its expression [18–20]. Moreover, high
miR-21 levels were found to be inversely correlated with
PDCD4 expression in a variety of tumors [18–24]. PDCD4
knockdown stimulated the invasion of colon cancer HT29
cells and inhibited E-cadherin expression. The reduced
levels of E-cadherin elicited an accumulation of active
β-catenin in the nuclei with a reported stimulation of
β-catenin/T cell factor (TCF)-dependent transcription of
genes such as uPAR and c-Myc [25, 26].
Persistent activation of signal transducer and
activator of transcription-3 (STAT3) is frequently
associated with malignant transformation [27]. Recent
studies implicate STAT3 as a vital regulator of microRNA
(miRNA) expression, and in addition, the STAT3 signaling
pathway is controlled by several specific miRNAs
[28–31]. There are two phylogenetically conserved STAT3
binding sites in miR-21 that regulate its oncogenic activity
[30]. It has been reported that transcriptional activation
of miR-21 by STAT3 leads to the induction of a stable
transformed state in cancer cell lines [28]. Members of the
IL-6 cytokine family are involved in a variety of biological
responses, and the autocrine secretion of IL-6 contributes
to cellular transformation via STAT3 phosphorylation [32].
In the present study, we investigated the interactive
role of miR-21-PDCD4 signaling in Cr(VI)-induced
malignant cell transformation. We found that chronic
Cr(VI) exposure increased miR-21 levels and was
associated with inhibition of PDCD4 expression and
malignant cell transformation. Importantly, Cr(VI)-induced
ROS was essential for the miR-21 elevation and PDCD4
reduction. In addition, STAT3 transcriptional activation by
IL-6 was crucial for the Cr(VI)-induced miR-21 elevation.
Furthermore, PDCD4 reduction by Cr(VI) suppressed
downstream protein E-cadherin expression, and led to the
β-catenin/TCF-dependent transcription of uPAR and c-Myc.
These results suggest that miR-21 and PDCD4 are critical
components of Cr(VI)-induced malignant transformation.

the oncogenic microRNA miR-21 [33]. In this study we
first examined whether acute treatment with Cr(VI) can
increase miR-21 expression and downregulate its target
tumor suppressor protein PDCD4. We observed a dosedependent and significant (p < 0.05) elevation in the miR21 levels associated with a dose-dependent decrease in
PDCD4 expression by RT-PCR and Western blot analysis
respectively in human bronchial epithelial BEAS-2B
cells treated with Cr(VI) (Figure 1A and 1B). Similar
results were observed by immunofluorescence analysis
of PDCD4, where acute treatment of Cr(VI) diminished
the PDCD4 expression in the nucleus (Figure 1C). There
was a significant decrease in the PDCD4 3ʹ-UTR reporter
activity when cells were treated with 5 μM Cr(VI) for 6 h,
whereas reporter activity was upregulated when miR-21
gene expression was inhibited (Figure 1D). These results
support the assumption that acute Cr(VI) treatment
increases the miR-21 levels with an associated decrease
in PDCD4 expression.

Cr(VI) regulates the downstream targets of
PDCD4 -E-Cadherin, β-catenin and TCF4
Previous studies demonstrated that knock-down
of PDCD4 down-regulates E-cadherin and increases
β-catenin and TCF4 protein expression [26]. In the current
study, acute treatment of BEAS-2B cells with Cr(VI)
down-regulated E-cadherin protein expression with an
associated up-regulation of active β-catenin (nuclear
translocated form) and TCF4, whereas the level of total
β-catenin remained unchanged (Figure 1E).

ROS generation is critical to effect an acute
Cr(VI)-induced miR-21 –PDCD4 signaling
cascade
A critical question for this investigation was whether
Cr(VI)-induced ROS plays any role in miR-21 –PDCD4
signaling. Cr(VI)-induced ROS production was quantified
by flow cytometry using the fluorescent probes DHE
and DCFDA. Cr(VI) exposure dramatically stimulated
O2.− and H2O2 generation in BEAS-2B cells, as indicated
by an increase of DHE (Figure 2A–2C) and DCFDA
(Figure 2E–2G) fluorescence intensity, respectively, when
levels were compared to those generated from untreated
control cells. The DHE signal was increased by Cr(VI) and
LY83853 (O2.− donor) and inhibited by MnTMPyP, cellpermeable SOD mimetic (O2.− scavenger) (Figure 2D).
Similarly, the DCFDA signal was increased by Cr(VI) and
H2O2, and inhibited by CAT (H2O2 scavenger) (Figure 2H).
The fluorescence intensity stimulated by Cr(VI) was also
abolished by apocynin (APO), a NOX inhibitor. Further,
the Cr(VI)-induced •OH generation in BEAS-2B cells was
detected by Electron spin resonance (ESR) (Figure 2I).
As shown in Figure 2J, Cr(VI) exposure induced a drastic
increase in NOX activity within 6 h and lasted for up to

RESULTS
Cr(VI) increases miR-21 and targets PDCD4
Earlier studies showed that PDCD4, a novel
tumor suppressor is an important functional target of
www.impactjournals.com/oncotarget
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24 h. Moreover we found that acute Cr(VI) treatment
also increased the expression of p47phox, one of the
NOX subunits (Figure 2K). Taken together, these results
suggest that Cr(VI) exposure induces ROS production in
BEAS-2B cells, and activation of NOX is required for this
ROS generation.
Next we sought the role of Cr(VI)-induced ROS
generation in miR-21- PDCD4 signaling. As outlined
above, we demonstrated that ROS plays an essential
role in Cr(VI)-induced miR-21 elevation and PDCD4
suppression. However, the Cr(VI)-induced miR-21
elevation and PDCD4 suppression were markedly reversed

by treatment with the ROS inhibitors, NAC or Catalase
(Figure 2L–2M). These results provide solid evidence that
ROS plays a key role in Cr(VI)-induced miR-21 elevation
and PDCD4 reduction.

STAT3 binding to the miR-21 promoter upon
IL-6 induction by Cr(VI)
Previous studies showed that Cr(VI) stimulates
IL-6 mRNA levels and STAT3 phosphorylation in human
airway epithelial cells [34]. STAT3 binding to the miR-21
promoter upon IL-6 induction has been reported previously

Figure 1: Cr(VI) increases miR-21 and targets PDCD4. BEAS-2B cells were exposed to increasing concentrations (0–5 μm) of

Cr(VI) for 24 h. (A) The relative miR-21 level was determined by Taqman real-time PCR. (B) Immunoblot analysis of PDCD4 protein
levels after acute Cr(VI) treatment. (C) Representative images of fluorescence immunostaining of PDCD4 (D) Cr(VI) increases the binding
of miR-21 to the 3′-UTR of PDCD4. BEAS-2B cells were transfected with renilla reporter construct (pGL3-PDCD4_3ʹ-UTR), miR-21
inhibitor (100 nM), negative control (100 nM), and pGL3-promoters and treated with 5 μM Cr(VI) for 6 h. Cellular lysates were subjected
to a luciferase reporter analysis as described in Materials and Methods. The results are expressed as a relative activity (relative luminescence
units (RLU)) normalized to the luciferase activity in the vector control cells without treatment. (E) Immunoblot analysis demonstrates that
acute treatment of Cr(VI) decreases E-cadherin levels associated with an increase in β-catenin and TCF4 protein levels in BEAS-2B cells.
Data presented in the bar graphs are the mean ± SD of three independent experiments. *indicates a statistically significant difference from
control cells with p < 0.05.
www.impactjournals.com/oncotarget
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[30]. To verify that IL-6 induces STAT3 binding to the
miR-21 promoter after Cr(VI) treatment, we analyzed
IL-6 levels and STAT3 activation by ELISA, and STAT3
binding to the miR-21 promoter by ChIP assay. Acute
Cr(VI) treatment to BEAS-2B cells significantly (p < 0.05)
increased the IL-6 levels (Figure 3A), STAT3 activation
(Figure 3B), and STAT3 phosphorylation (Figure 3C) in
a dose-dependent manner. In addition, Cr(VI) treatment

also increased the binding of STAT3 on miR-21 promoter
(Figure 3D–3E). A genomic DNA fragment extending from
−1120 to +25 bp relative to the miR-21 transcription start
site containing the putative STAT3 enhancer region proved
to be IL-6–responsive in a reporter assay [30]. As shown
in Figure 3F, miR-21 promoter activity was significantly
(p < 0.05) elevated by Cr(VI) or IL-6, while STAT3 knock
down (siSTAT3) inhibited miR-21 promoter activity.

Figure 2: ROS generation is critical to effect an acute Cr(VI)-induced miR-21 –PDCD4 signaling cascade.

Cr(VI) induces ROS generation. Generation of O2.- and H2O2 were determined by staining the cells with DHE and DCFDA, respectively.
BEAS-2B cells were exposed to Cr(VI) (0 to 5 µM) for 12 h and then were labeled with (A–C) DHE (10 µM) or (E–G) DCFDA (10 µM).
Images were obtained by fluorescence microscopy and fluorescent intensity was determined by flow cytometry. BEAS-2B cells were
exposed to Cr(VI) (0 or 5 µM) or were pretreated with MnTMPyP (5 µM; O2.- scavenger), CAT (1000 U/ml; H2O2 scavenger), or APO
(50 µM; NOX inhibitor) for 2 h followed by Cr(VI) (5 µM) treatment for 6 h and then were labeled with (D) DHE (10 µM) or (H) DCFDA
(10 µM) as described in the Materials and Methods section. LY83853 (10 µM) and H2O2 (0.1 mM) were used as positive controls for DHE
and DCFDA measurements, respectively. (I) Generation of .OH was determined by ESR. (J) NOX activity was measured by the lucigenin
chemiluminescence assay. (K) Cr(VI) increases the protein levels of NOX subunit, p47phox. Exogenous addition of ROS inhibitors catalase
or NAC inhibited the acute Cr(VI)- induced (L) miR-21 increase and (M) PDCD4 suppression. Data presented in bar graphs are the
mean ± SD of three independent experiments. *and #indicate statistically significant differences compared to control without treatment or
H2O2 /LY83853/ Cr(VI) treatment, respectively with p < 0.05.
www.impactjournals.com/oncotarget
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miR-21 elevation and PDCD4 suppression
contribute to Cr(VI)-induced malignant cell
transformation

with Cr(VI) for six months and showed a marked decrease
in the PDCD4 level (Figure 4G). These observations
clearly emphasize a role for miR-21-PDCD4 signaling in
Cr(VI)-induced transformation.

Chronic Cr(VI) exposure induces malignant
transformation in BEAS-2B cells [3]. Malignant cell
transformation was assessed by anchorage-independent
growth in soft agar [35]. Long term (6 months) treatment
with low concentrations (0.125, 0.25 and 0.5 μM) of
Cr(VI) induced malignant transformation of BEAS-2B
cells as shown by the marked increase in size and number
of colonies compared to untreated control (Figure 4A–4B).
A similar trend was observed with the clonogenic assay,
where chronic Cr(VI) exposure to BEAS-2B cells showed
a significant (p < 0.05) and dose-dependent increase in
colony number (Figure 4C–4D).
We treated BEAS-2B cells with various
concentrations (0.125, 0.25 and 0.5 μM) of Cr(VI) and
measured the miR-21 levels and PDCD4 expression at
two, four and six months. We found a dose-dependent
and significant (p < 0.05) increase in the miR-21 levels
(Figure 4E) associated with a dose-dependent and drastic
decrease in the PDCD4 expression (Figure 4F) with
chronic Cr(VI) exposure. Similar results were observed by
immunofluorescence, when BEAS-2B cells were treated

PDCD4 suppression by Cr(VI) down-regulates
E-cadherin and increases the accumulation of
β- catenin and TCF4 in the nucleus
Previous studies reported that suppression of PDCD4
elicits an inhibition of E-cadherin expression, which
is associated with an increase in β- catenin activation
and TCF4 expression [26]. To evaluate this, we treated
BEAS-2B cells with different concentrations of Cr(VI)
for six months. As shown in Figure 5A, chronic Cr(VI)
exposure resulted in decreased E-cadherin protein levels,
while active β- catenin and TCF4 expressions increased,
and these effects occurred in a dose-dependent manner.
In confirmation, immunofluorescence analysis indicated
that chronic Cr(VI) exposure decreased E-cadherin
expression (Figure 5B) and increased β- catenin and TCF4
accumulation in the nucleus (Figure 5C–5D). These data
clearly show that chronic Cr(VI) exposure suppresses
E-cadherin and increases the accumulation of β- catenin
and TCF4 in the nucleus during malignant transformation.

Figure 3: STAT3 binding to the miR-21 promoter upon IL-6 induction by Cr(VI). BEAS-2B cells were treated with Cr(VI)

(2.5 and 5 μM) for 24 h. Culture medium was collected to estimate the (A) IL-6 level using commercially available ELISA kit according
to manufacturer’s recommendation. (B) STAT3 activity was measured in the nuclear fraction of cell lysates using ELISA following the
manufacturer’s protocol. (C) Total cell lysates were prepared for Western blot analysis using specific antibodies against pSTAT3 and
STAT3. (D–E) BEAS-2B cells were exposed with IL-6 or Cr(VI) for 30 minutes and subjected to a chromatin immunoprecipitation (ChIP)
analysis using anti-STAT3 or IgG isotype control. Coimmunoprecipitated DNA was amplified by PCR with primers specific for the miR-21
upstream enhancer. (F) Reporter gene assays were performed in BEAS-2B cells transfected either with a luciferase vector driven by the
miR-21 promoter/enhancer alone (−) or in the presence of a vector encoding a small hairpin RNA silencing STAT3 expression (siSTAT3).
Data presented in the bar graphs are the mean ± SD of three independent experiments. *indicates a statistically significant difference
compared to control with p < 0.05.
www.impactjournals.com/oncotarget

51197

Oncotarget

PDCD4 suppression by Cr(VI) increases the
expression of uPAR and c-Myc

showed a 3-fold increase for invasion compared to
untreated control cells (Figure 6C). A previous study
demonstrated that in PDCD4 knock down cells, β-catenin
binds with TCF4 in the nucleus, with subsequent binding
of β-catenin/TCF4 complex to the uPAR and c-Myc
promoters [26]. To investigate this mechanism for Cr(VI)induced carcinogenesis, we performed ChIP analysis using
a TCF4 antibody and primers that specifically amplify the
β-catenin/TCF4 binding site on the promoters of uPAR
(–308 to –302) and c-Myc (–452 to –446). As shown in
Figure 6D–6E, association of the β-catenin/TCF4 complex
to the uPAR and c-Myc promoters increased during
chronic Cr(VI) treatment in a dose-dependent manner.
These results indicate that PDCD4 suppression increases
uPAR and c-Myc expressions, and also activates β-catenin/

The c-Myc oncogene plays a vital role at both early
and late stages of carcinogenesis [36]. uPAR is involved
in cancer cell invasion and significantly correlates to
tumor aggressiveness and poor outcome [37]. It has been
reported that uPAR and c-Myc are the target genes of
β-catenin/TCF4 dependent transcription [26]. As shown in
Figure 6A, chronic Cr(VI) exposure increased c-Myc and
uPAR expressions in BEAS-2B cells in a dose-dependent
manner. Similarly, the invasive potential of BEAS-2B
cells under chronic Cr(VI)-exposure was also increased
in correlation with uPAR expression (Figure 6B–6C).
BEAS-2B cells treated with 0.5 µM Cr(VI) for 6 months

Figure 4: Cr(VI)-induced miR-21 increase and PDCD4 suppression contribute to malignant cell transformation.

BEAS-2B cells were maintained in a medium containing various concentrations of Cr(VI) (0.125, 0.25 and 0.5 µM) for 6 months. (A–B)
Cells were cultured in 0.35% soft agar for 5 weeks. The number of colonies in the entire dish was counted. (C–D) Cells (300 cells) from
indicated Cr(VI) treatments were seeded into each of three dishes (60 mm diameter), and grown for an additional 10 days and stained with
crystal violet. Colony numbers in the entire dish were counted. (E) The relative miR-21 level was determined by Taqman real-time PCR.
(F) PDCD4 protein levels after chronic Cr(VI) treatment was detected by immunoblot analysis. The three panels show data obtained at 2,
4 and 6 months of treatment. (G) Representative images of fluorescence immunostaining for PDCD4. Data presented in the bar graphs are
the mean ± SD of three independent experiments. *indicates a statistically significant difference compared to control with p < 0.05.
www.impactjournals.com/oncotarget
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TCF4 complex binding to the uPAR and c-Myc promoters
during chronic Cr(VI) exposure.

in miR-21 levels even after chronic Cr(VI) treatment.
BEAS-2B cells with miR-21 knock down also blocked the
suppression of its target tumor suppressor, PDCD4 that
normally occurs with chronic Cr(VI) treatment (Figure
7B). Importantly, miR-21 knock down significantly
inhibited the chronic Cr(VI)-induced malignant cell
transformation (Figure 7C) and invasion (Figure 7D).
Similarly over-expression of PDCD4 (Figure 7E) in
BEAS-2B cells significantly (p < 0.05) decreased the
chronic Cr(VI)-induced malignant cell transformation
(Figure 7F) and invasion (Figure 7G). These results
demonstrated that the increased levels of oncomiR

Stable knockdown of miR-21 and overexpression
of PDCD4 inhibit Cr(VI)-induced malignant cell
transformation and invasion
To determine the oncogenic role of miR-21 in
Cr(VI)-induced malignant transformation and invasion,
BEAS-2B cells with stable knocked down of miR-21 were
treated with Cr(VI) (0.5 μM) for six months. As shown in
Figure 7A, miR-21 knock down cells showed no increase

Figure 5: PDCD4 suppression by Cr(VI) down-regulates E-cadherin and increases the accumulation of β- catenin
and TCF4 in the nucleus. BEAS-2B cells were maintained in a medium containing various concentrations of Cr(VI) (0.125, 0.25 and

0.5 µM) for 6 months. (A) Total cell lysates were prepared for Western blot analysis using specific antibodies against E-Cadherin, Activeβ-catenin, β-catenin, TCF4 and GAPDH. Representative images of fluorescence immunostaining of (B) E-cadherin (C) β- catenin and
(D) TCF4.
www.impactjournals.com/oncotarget
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miR-21 and suppression of tumor suppressor PDCD4 are
critically important for Cr(VI)-induced malignant cell
transformation and invasion.

Elevated miR-21 and suppressed PDCD4
expression in Cr(VI)-exposed animals and
xenograft tumors

Antioxidants inhibit chronic Cr(VI)-induced
miR-21 elevation and PDCD4 suppression

To explore whether Cr(VI) exposure causes miR21 elevation and PDCD4 suppression in vivo, BALB/c
mice were nasally exposed to insoluble Cr(VI) particles
(1.2 mg/ml) for up to 3 months. The results show that
chronic Cr(VI) exposure at 1.2 mg/ml induced an increase
in miR-21 levels (Figure 8A) and decreased PDCD4
expression (Figure 8B–8C) in mouse lung tissue compared
to control. Next we investigated tumorogenicity in nude
mice using BEAS-2B cells chronically exposed to Cr(VI).
For this study, nude mice were injected sc with BEAS2B cells that had been exposed to Cr(VI) for 6 months
at the indicated concentration. Over a 4-week period post
inoculation, we observed visible tumor formation that
increased progressively in size for mice injected with
Cr(VI)-treated BEAS-2B cells but not in those injected
with control cells (Figure 8D–8E). Consistent with our
in vitro findings above, we found significantly increased
miR-21 levels (Figure 8F) associated with decreased

To investigate the role of antioxidants on
chronic Cr(VI)-induced miR-21 elevation and PDCD4
suppression, we treated BEAS-2B cells overexpressing
catalase with Cr(VI) (0.5 μM) for six months. Our
study shows that overexpression of catalase noticeably
decreased the miR-21 elevation induced by chronic
Cr(VI) treatment (Figure 7H) and suppressed the PDCD4
reduction (Figure 7I) in BEAS-2B cells with chronic
Cr(VI) treatment. Furthermore, catalase overexpression
also decreased the chronic Cr(VI)-induced malignant
cell transformation (Figure 7J) and invasion (Figure 7K).
These observations clearly demonstrate the indispensable
role of ROS in regulating miR-21-PDCD4 signaling during
chronic Cr(VI)-induced malignant cell transformation and
invasion.

Figure 6: PDCD4 suppression by Cr(VI) increases the expression of uPAR and c-Myc. BEAS-2B cells were exposed to

various concentrations of Cr(VI) (0.125, 0.25 and 0.5 µM) for 6 months. (A) Expression levels for uPAR and c-Myc were analyzed by
Western blot. To evaluate invasive capacity (B–C) 1 × 105 cells from each group were seeded on the top chamber of 24-well plate culture
inserts coated with 20 μl of matrigel in duplicate. Cells were cultured for additional 48 h. Invaded cells on the bottom of insert were stained
and quantified. (D–E) For the ChIP assay, TCF4 binding regions on uPAR and c-Myc promoters were identified. Chromatin isolated from
chronic Cr(VI) exposed BEAS-2B cells were immunoprecipitated with an anti-TCF4 antibody or control mouse IgG. The TCF4 binding
to the uPAR and c-Myc promoters was analyzed by RT PCR with specific primers. Data presented in the bar graphs are the mean ± SD of
three independent experiments. *indicates a statistically significant difference compared to control with p < 0.05.
www.impactjournals.com/oncotarget
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PDCD4 expression (Figure 8G) in xenograft tumors
generated with chronic Cr(VI) exposed BEAS-2B cells.
In addition we also demonstrated that stable knockdown
of miR-21 or overexpression of PDCD4 in BEAS-2B cells
chronically exposed to Cr(VI) reduced tumorogenicity
in nude mice. For these studies, BEAS-2B cells stably
expressing miR-21 shRNA, PDCD4, or vector, with or
without Cr(VI) exposure for 6-month, were injected to
nude mice. Four weeks after injection, tumor development
was assessed. Tumors developed from BEAS-2B cells
with stable knockdown of miR-21 and exposed to Cr(VI)
(Figure 8H), and tumors formed from Cr(VI)-exposed
BEAS-2B cells overexpressing PDCD4 (Figure 8I) were
smaller than those of Cr(VI)-exposed-vector cells. To
confirm these results, we examined the basal levels of

miR-21 and PDCD4 in a variety of lung cancer cell lines.
Our results showed increased miR-21 levels (Figure 8J)
and decreased PDCD4 expression (Figure 8K) in the lung
cancer cells (H2030, H460, H23, and A549) compared to
normal lung epithelial cells (BEAS-2B and NL-20).

The levels of miR-21 increase and PDCD4
decrease in human lung adenocarcinoma tissue
The expression levels of miR-21 and its downstream
target protein PDCD4 were determined by real time PCR
and florescence immunohistochemistry respectively
in lung tissues from lung adenocarcinoma patients. As
shown in Figure 9A, there was a 6-fold increase in miR21 level in lung cancer tissues compared to the normal

Figure 7: Stable knockdown of miR-21 and overexpression of PDCD4 or catalase inhibit Cr(VI)-induced malignant
cell transformation and invasion. (A–D) BEAS-2B cells were stably knockeddown with miR-21 shRNA or their corresponding
vehicle vector and exposed to Cr(VI) (0 or 0.5 µM) for 6 months. (A) the relative miR-21 level was determined by Taqman real-time PCR.
(B) Cell lysates were prepared to determine the protein level of PDCD4 using Western blot analysis. (C) Anchorage-independent colony
growth was assessed as previously described. (D) Cell invasion was assessed as described previously (E-G) BEAS-2B cells were stably
overexpressed with PDCD4 or their corresponding vehicle vector and exposed with Cr(VI) (0 or 0.5 µM) for 6 months. (E) Cell lysates
were prepared to determine the protein level of PDCD4 by Western blot analysis. (F) Anchorage-independent colony growth and (G) cell
invasion were assessed as previously described. (H-K) BEAS-2B cells were stably overexpressed with catalase or their corresponding
vehicle vector and exposed with Cr(VI) (0 or 0.5 µM) for 6 months. (H) The relative miR-21 level was determined by Taqman realtime PCR. (I) PDCD4 protein levels after chronic Cr(VI) treatment was detected by immunoblot analysis. (J) Anchorage-independent
colony growth and (K) cell invasion were assessed as previously described. Data presented in the bar graphs are the mean ± SD of three
independent experiments. * indicates a statistically significant difference compared to control with p < 0.05.
www.impactjournals.com/oncotarget
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tissues from same patients. However, the expression
levels of PDCD4 were decreased in all lung cancer tissues
when compared with normal tissues as determined by
florescence immunohistochemistry (Figure 9B). Moreover,
phosphorylated STAT3 was also increased in lung tumor
tissues of patients (Figure 9C). These results demonstrate
the indispensable role of the miR-21-PDCD4 signaling
axis in lung carcinogenesis.

exposure is one of the major causes of carcinogenesis
[3, 45, 43, 44]. Although Cr(VI) is a well-established
carcinogen, relatively little is known about the molecular
mechanisms of Cr(VI)-induced malignant transformation.
In this study we detail a mechanism for Cr(VI)-induced
malignant transformation and the involvement of a
miR-21-PDCD4 signaling process.
MicroRNA’s (miRs) are important posttranscriptional regulators that influence more than 30% of
human mRNAs. Significant changes in microRNA (miR)
expression in response to environmental exposure in
humans have recently been reported [46, 47]. Notably miR21, a key oncogene, plays an important role in the initiation
and progression of cancer [47] and is highly overexpressed
in most cancers [48, 49]. miR-21 binds to the 3′-UTR of

DISCUSSION
Occupational exposure to Cr(VI) is a wellestablished cause of lung cancer [38–41], therefore,
Cr(VI) is considered a class I carcinogen [42]. Several
studies have shown that ROS generated by Cr(VI)

Figure 8: Increased miR-21 and suppressed PDCD4 expression in Cr(VI)-exposed animals and xenograft tumors.

(A–C) Female BALB/c mice were treated intranasally with either insoluble Cr (VI) (1.2 mg/ml) or PBS (vehicle control), once a day, 5 days/
week. After 3 months, mice were euthanized using CO2 and lung tissue was isolated for further examination. (A) The relative miR-21 level
was determined by Taqman real-time PCR. PDCD4 protein expression was detected by (B) immunohistochemistry and (C) immunoblot
analysis. (D–G) Nude mice were injected sc with BEAS-2B cells exposed to indicated concentration of Cr(VI) for 6 months. After 4 weeks,
mice were euthanized using CO2 and tumor was isolated for further examination. (D–E) Tumor volume was measured and (F) the relative
miR-21 level was determined by Taqman real-time PCR. (G) PDCD4 protein expression was detected by immunohistochemistry. (H-I)
Inhibition of in vivo tumor growth in nude mice with miR-21 knockdown and PDCD4 overexpression in chronic Cr(VI)-exposed BEAS-2B
cells. BEAS-2B cells with (H) miR-21 knockdown, (I) PDCD4 overexpression and respective vector controls were exposed to Cr(VI) (0 or
0.5 μM) for 6 months, xenograft growth of tumors in nude mice was performed as described previously. (J–K) Different lung cancer cell
lines were used to determine the basal levels of (J) miR-21 and (K) PDCD4 expression. Data presented in the bar graphs are the mean ± SD
of three independent experiments. * indicates a statistically significant difference compared to control with p < 0.05.
www.impactjournals.com/oncotarget

51202

Oncotarget

the tumor suppressor PDCD4 to suppress its translation [4].
Down-regulation of PDCD4 expression by miR-21 leads to
tumor cell growth, survival, chemoresistance, invasion and
metastasis [4, 50]. Inhibition of miR-21 or overexpression
of PDCD4 results in decreased tumor formation and
growth [51]. Therefore, miR-21 and PDCD4 are potential
targets for novel cancer prevention and therapeutics. In our
preliminary analysis, we found increased miR-21 levels
and decreased PDCD4 expressions in lung cancer cell lines
(H2030, H460, H23, and A549) compared to those found
in normal lung epithelial cells (BEAS-2B and NL-20).
We investigated the effect of Cr(VI) on the interaction of
miR-21-PDCD4 signaling and subsequent malignant cell
transformation; both acute and chronic treatments of Cr(VI)
induce miR-21 increases with an associated suppression
of PDCD4. Cr(VI) also increased the binding of miR-21
to the 3′-UTR of PDCD4. Moreover, the increased miR21 and reduced PDCD4 levels brought about by chronic
Cr(VI) treatments in BEAS-2B cells also induced malignant
transformation. Furthermore, stable shut down of miR21 and overexpression of PDCD4 in BEAS-2B cells
significantly inhibited the chronic Cr(VI)-induced malignant
transformation. These results strongly demonstrate that this
interactive miR-21-PDCD4 signaling plays an important
role in Cr(VI)-induced malignant transformation.
We also explored the mechanisms by which Cr(VI)
activates miR-21. STAT3, known to be important for
cancer initiation and tumor progression, was reported to
bind directly to the miR-21 promoter upon IL-6 induction
[28, 30, 52]. In our study treatment of BEAS-2B cells with
Cr(VI) significantly increased IL-6 secretion. In addition
Cr(VI) also triggered STAT3 transcriptional activation
and phosphorylation. Furthermore, the binding of STAT3
on the miR-21 promoter was also increased with Cr(VI)
treatment. These data clearly suggest that Cr(VI)-induced
IL-6 secretion mediates STAT3 activation, which is crucial
for the rise in miR-21.
Studies suggest that hydrogen peroxide (H2O2)
can up-regulate miR-21 levels and decrease PDCD4
expression in vascular smooth muscle cells [53]. It is
also established that Cr(VI)-induced ROS is crucial to
malignant cell transformation [3]. However, the role
of Cr(VI)-induced ROS in miR-21-PDCD4 signaling
and malignant transformation is currently unclear. We
demonstrated that Cr(VI) induces ROS and that p47phox,
one of the NOX subunits is the key source Cr(VI)-induced
ROS. Moreover, exogenous treatment of cells with catalase
or NAC significantly inhibited the Cr(VI)-induced a rise
in miR-21 and decreased PDCD4 levels. To substantiate
a role for antioxidants in the Cr(VI)-induced malignant
cell transformation mediated by increased miR-21 levels
and PDCD4 suppression, we chronically treated BEAS-2B
cells overexpressing catalase with Cr(VI) for six months.
Interestingly, catalase overexpression in BEAS-2B cells
significantly inhibited Cr(VI)-induced miR-21 elevation,
PDCD4 suppression and malignant cell transformation.
www.impactjournals.com/oncotarget

A disturbance in epithelial cell adhesion, which
leads to a more invasive and metastatic phenotype, is a
hallmark of tumor progression [54]. E-cadherin, a wellknown primary transmembrane glycoprotein molecule
is involved in Ca2+ -dependent cell–cell adhesion
in epithelial tissues. Several studies report a strong
correlation between E-cadherin loss and the initiation and
progression of tumors [26, 54]. The cytoplasmic domain
of E-cadherin is attached to actin microfilaments via two
other molecules, α- and β-catenin [55]. Disruption of these
E-cadherin homotypic interactions results in the release of
β -catenin from E-cadherin and subsequent translocation
of β -catenin into the nucleus; the nuclear β-catenin
associates with TCF4 (a member of transcription factor
family) to form a β-catenin/TCF complex and activates
the transcription of genes involved in cancer initiation,
progression and metastasis such as c-Myc, and uPAR
[26]. Down-regulation of PDCD4 leads to an inhibition
of E-cadherin expression, which is associated with an
increase in β- catenin/TCF4 dependent transcription
[26]. In our study both acute and chronic treatment
with Cr(VI) suppressed the E-cadherin expression, and
was accompanied by an increased active β- catenin and
TCF4 expression in BEAS-2B cells in a dose-dependent
manner. In addition, chronic Cr(VI) exposure increased
uPAR and c-Myc protein expressions in BEAS-2B cells,
as well as their invasive potential. Furthermore, chronic
Cr(VI) exposure increased the binding of TCF4 on
uPAR and c-Myc promoters in BEAS-2B cells. These
findings indicate that PDCD4 suppression is critical for
the β-catenin/TCF dependent transcription of c-Myc, and
uPAR in Cr(VI)-induced carcinogenesis.
To explore whether Cr(VI) exposure causes miR21 elevation and PDCD4 suppression in vivo, BALB/c
mice were nasally exposed to insoluble Cr(VI) particles
for 3 months. We found an increase in miR-21 levels
associated with PDCD4 suppression in the lungs of mice
exposed to Cr(VI). Moreover, we found an significantly
increased miR-21 levels associated with decreased PDCD4
expression in xenograft tumors generated with chronic
Cr(VI) exposed BEAS-2B cells. In addition we confirmed
that stable knockdown of miR-21 or overexpression of
PDCD4 reduce the tumorigenicity of chronic Cr(VI)
exposed BEAS-2B cells in nude mice. Similar results were
observed in lung adenocarcinoma tissues from patients
compared with normal tissues from same patients.
In summary, we found that chronic Cr(VI) exposure
increases miR-21 levels with an associated inhibition of
PDCD4 expression, and cause malignant transformation
in BEAS-2B cells. Cr(VI) triggers the miR-21 increase
via the IL-6/STAT3 pathway. Cr(VI)-induced PDCD4
suppression down-regulates the E-cadherin protein
expression along with an upregulation of active β-catenin
(nuclear translocated form) and TCF4 in BEAS-2B cells.
In addition, Cr(VI) exposure increases uPAR and c-Myc
expressions, and also activates β-catenin/TCF4 complex
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binding to the uPAR and c-Myc promoters. Stable
knockdown of miR-21 or overexpression of PDCD4
reduces the tumorogenicity of chronic Cr(VI) exposed
BEAS-2B cells in nude mice (Figure 9D). In short, our
findings demonstrate an indispensable role for an miR-21PDCD4 signaling axis in Cr(VI)-induced malignant cell
transformation and lung carcinogenesis.

Cayman Chemical (Ann Arbor, MI). Human miR-21
hairpin inhibitor was purchased from Thermo Fisher
Scientific Dharmacon (Chicago, IL, USA). Antibodies
against PDCD4 (CST#9535), E-cadherin (CST#3195),
β-catenin (CST#8480), c-Myc (CST#5605), uPAR
(CST#9692), pSTAT3 Tyr705 (CST#9145) and STAT3
(CST#9139) were purchased from Cell Signaling
Technology (Danvers, MA). Anti–active-β-catenin
(clone 8E7#05-665) antibody was purchased from EMD
Millipore (Billerica, MA). Antibodies against TCF4
(sc-13027) and GAPDH (sc-25778) were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

MATERIALS AND METHODS
Antibodies and chemicals
Potassium dichromate (K2Cr2O7), apocynin
(APO), 5,5-dimethyl-1-pyrroline-1-oxide (DMPO),
were purchased from Sigma-Aldrich (St Louis, MO).
Both Dichlorodihydrofluoresceine acetate (DCFDA) and
dihydroethidium (DHE) were purchased from Molecular
Probes (Eugene, OR). Manganese(III) tetrakis(1-methyl4-pyridyl) porphyrin (MnTMPyP) was purchased from

Cell lines and cell culture
Human bronchial epithelial cell lines BEAS-2B,
NL20 and other lung cancer cell lines H2030, H460, H23,
A549 cells were obtained from the American Type Culture
Collection (Rockville, MD). Chromium transformed cells

Figure 9: The levels of miR-21 and PDCD4 in lung adenocarcinoma. Lung adenocarcinoma tissues from patients was used

to demonstrate the (A) relative miR-21 level compared to normal tissue from same patients. (B) PDCD4 protein expression was detected
by immunofluorescence and (C) STAT3 phosphorylation was determined by immunohistochemistry. Data presented in the bar graphs
are the mean ± SD of three independent experiments. *indicates a statistically significant difference compared to control with p < 0.05.
(D) Proposed mechanism of Cr(VI)-induced malignant cell transformation and carcinogenesis.
www.impactjournals.com/oncotarget
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(CrT) were generated as described previously [45]. NL20
cells were grown at 37°C in humidified air containing
5% CO2 in serum-free LHC-9 medium. BEAS-2B and
CrT cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM), while H2030, H460, H23, and A549
cells were cultured in RPMI 1640 supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine,
and 5% penicillin/streptomycin at 37°C in a humidified
atmosphere with 5% CO2 in air.
K2Cr2O7 was used for Cr(VI) treatments. For shortterm exposure of Cr(VI), cells were grown to 80–90%
confluent, and then the medium was replaced with DMEM
medium containing 0.1% FBS for overnight before
Cr(VI) treatment at the dose and duration indicated. In
some experiments, cells were first pretreated with various
inhibitors for 2 h and then exposed to Cr(VI). For chronic
exposure of Cr(VI), the cells were continuously cultured in
growth medium with the indicated concentration Cr(VI).

were screened and further cultured in DMEM medium
containing 1 µg/mL puromycin and selected through
FACS (Fluorescent Assisted Cell Sorting system).

Intracellular ROS determination
H2O2 and O2.- generations were examined using
the fluorescent dye DCFDA and DHE, respectively,
as described previously [45]. The cells were cultured
in 6-well plates (2 × 105 cells/well), treated with 5 μM
of Cr(VI) for 12 h and incubated with DCFDA or DHE
(10 μM) for 40 min at 37°C. Trypsinized cells were washed
twice with cold PBS, and analyzed by fluorescenceactivated cell sorting (FACS Calibur, BD Biosciences).
The fluorescence intensity of DCFDA was measured at an
excitation wavelength of 492 nm and an emission wave
length of 517 nm. The fluorescence intensity of DHE was
measured at an excitation wavelength of 535 nm and an
emission wavelength of 610 nm.

Plasmids and transfection

Electron spin resonance (ESR) assay

Plasmid DNA encoding human catalase and STAT3
shRNA were purchased from Origene (Rockville, MD).
PDCD4 3′-UTR reporter plasmid was kindly provided by
Dr. Yong Li (University of Louisville, USA). The STAT3miR-21 reporter was constructed as described previously
[30]. PcDNA3.1/PDCD4 plasmid was kindly provided by
Dr. Hsin-Sheng Yang (University of Kentucky, USA).
The overexpression of catalase or PDCD4 and
knockdown of STAT3 in BEAS-2B cells were performed
using Lipofectamine™2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Briefly, BEAS2B cells were seeded at approximately 50% confluency in
6-well culture plates and transfected with 4 μg plasmid.
Cell clones resistant to G418 were isolated; overexpression
of CAT and PDCD4 protein production were confirmed by
immunoblotting.
The
pLenti-III-miR-Off-has-miR-21-puro-GFP
expression vector and the negative control vector pLentiIII-miR-Off- puro-GFP were purchased from Applied
Biological Materials, Inc. (Richmond, CA). Human
embryonic kidney 293T cells (ATCC, Manassas, VA)
were transfected with lentiviral packaging vectors (ABM,
Richmond, BC, CA) and lentiviral vectors expressing
miR-Off-has-miR-21-puro-GFP or miR-Off- puro-GFP
by Lipofectamine™2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol [56].
For generating stable miR-21 knockdown cell
lines, two days after transfection, supernatants containing
viral particles were harvested and used to infect BEAS2B cells at approximately 70% confluence in DMEM
supplemented with 8 μg/ml of polybrene using lentifectin
reagent (ABM technologies) following the manufacture’s
protocol. 72 h after transfection, the medium was changed
to the selection DMEM with 10% FBS and supplemented
with puromycin 1 μg/mL (sigma) to screen stable cell
lines for further assay. Three weeks later, the cell clones
www.impactjournals.com/oncotarget

ESR measurement was conducted using a Bruker
EMX spectrometer (Bruker Instruments, Billerica, MA)
and a flat cell assembly. The intensity of ESR signal
was used to measure the amount of hydroxyl radical
generation. DMPO was used as a spin or radical trap.
DMPO was charcoal purified and distilled to remove all
ESR detectable impurities before use. Hyperfine couplings
were measured (to 0.1 G) directly from magnetic field
separation using potassium tetraperoxochromate (K3CrO8)
and 1,1-diphenyl-2-picrylhydrazyl (DPPH) as reference
standards. Reactants were mixed in test tubes to a total
final volume of 0.5 mL. The reaction mixture was then
transferred to a flat cell for ESR measurement.

Clonogenic assay
BEAS-2B cells (105 cells) were seeded into each
well of a 6-well plate and allowed to attach overnight.
After the indicated exposure, cells were collected by
trypsinization, three hundred cells were then reseeded
into each of three dishes (60 mm diameter), and grown for
10 days. The cells were fixed with 2% formalin for 10 min
and stained with 0.5% crystal violet stain and counted.

NOX activity assay
NOX activity was measured by the lucigenin
enhanced chemiluminescence method as described
previously [3]. Briefly, cells were harvested and
homogenized by sonication in cold lysis buffer (20 mM
KH2PO4, pH 7.0, 1 mM EGTA, 1 mM phenyl methyl
sulfonyl fluoride, 10 µg/ml aprotinin, and 0.5 µg/ml
leupeptin). Homogenates were centrifuged at 800 × g at
4°C for 10 min to remove the unbroken cells and debris,
and aliquots were used immediately. To start the assay,
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100-µl of homogenate supernatants were added to 900 µl
of 50 mM phosphate buffer, pH 7.0, containing 1 mM
EGTA, 150 mM sucrose, 5 µM lucigenin, and 100 µM
NADPH. Photon emission in terms of relative light units
was measured in a Glomax luminometer (Promega) every
30 s for 5 min. There was no measurable activity in the
absence of NADPH. Superoxide anion production was
expressed as relative chemiluminescence (light) units
(RLU)/mg protein.

The Cr(VI)-transformed cells from anchorageindependent colonies were selected and grown in DMEM.
Passage-matched cells without Cr(VI) treatment were used
as control.

Collagen matrix invasion assay

BEAS-2B cells transfected with the luciferase
reporter constructs were seeded into 24-well plates
(5 × 104/well) and subjected to various treatments when
cultures reached 80–90% confluence. Cellular lysates
were subjected to a luciferase reporter assay (Promega,
Madison, WI) using Glomax luminometer (Promega) as
described previously [45]. The results are expressed as
relative activity normalized to the luciferase activity in the
control cells without treatment.

Collagen matrix invasion assay was performed
as described previously [57]. Briefly, BEAS-2B cells
(105 cells/Transwell) chronically exposed to Cr(VI)
were seeded to the top chamber of invasion chamber and
incubated 24 h. Cells in top chamber (non-invaded) were
removed, and cells on bottom of filter insert (invaded)
were fixed with 3.7% paraformaldehyde and stained
with 0.5% crystal violet in 2% ethanol. Membranes were
washed and the dye was eluted with 10% acetic acid.
Absorbance was measured at 595 nm using a microtiter
plate reader (Beckman coulter). The number of invaded
cells was presented relative to untreated controls.
Experiments was performed in duplicate and repeated
3 times.

ELISA for IL-6 and STAT3

Chromatin immunoprecipitation (ChIP) assay

BEAS-2B cells were cultured in DMEM
supplemented with 10% FBS containing Cr(VI) (0, 2.5,
and 5 µM) for 24 h. Subsequently, the culture media
was collected and used to estimate IL-6 level using
commercially available IL-6 ELISA kit (BioLegend,
Inc. CA, USA) according to the manufacturers’
recommendation.
For quantitative analysis of STAT3, TransAM ELISA
kit (Active Motif, Carlsbad, CA) was used following
the manufacturer’s protocol. For this assay, the nuclear
extracts of cell samples from various treatment groups
were prepared using the Nuclear Extraction kit (Active
Motif) according to the manufacturer’s direction.
Absorbance was recorded at 450 nm with reference taken
at 650 nm. The assay was performed in duplicate and the
results are expressed as the percentage absorbance of
control group.

ChIP analysis was performed using a PierceTM
Agarose ChIP Kit (Thermo Scientific, Rockford, IL).
Sheared chromatin was diluted and immunoprecipitated
with 2 μg of anti-STAT3, anti-TCF4 or control IgG
antibody. DNA protein complexes were eluted from the
protein A/G agarose beads using a spin column and were
reverse cross-linked by incubating with NaCl at 65°C. The
relative TCF4 binding to the c-MYC and uPAR promoters
or STAT3 binding to miR-21 promoter was analyzed by
MyiQ™ Single-Color Real-Time PCR Detection System
(Bio-Rad, Hercules, CA) with SYBR Green PCR master
mix using following primer sequences, TCF4 binding to
c-Myc promoter: (F) GCGCCCATTAATACCCTTCT and
(R) TCTCCCTTTCTCTGCTGCTC; TCF4 binding to
uPAR promoter: (F) GGAAGCAAAGCAAGGGTTAAG
and (R) GCCCTGACTCATGGAGTTGT; STAT3 binding
to miR-21 promoter/enhancer (F) CCTCTGAGAAG
AGGGGACAA
and
(R)
ACCGCTTCCAGCA
AAAGAGT. General PCR amplification also performed
in a Mastercycler® thermal cycler (Eppendorf, Foster City,
CA).

Luciferase reporter assay

Anchorage-independent colony growth assay for
Cr(VI)-induced cell transformation
Soft agar colony formation assay was performed as
described previously [45]. BEAS-2B cells or BEAS-2B
cells with stable overexpression of catalase or PDCD4
or BEAS-2B cells with stable knockdown of miR-21
were treated with 0.5 µM Cr(VI). The fresh medium was
added every 3 days. After 24 weeks, 1 × 104 cells were
suspended in 3 mL culture medium containing 0.35%
agar and seeded into 6-well plates with 0.5% agar base
layer, and maintained in an incubator for 4 weeks. The
colonies greater than 0.1 mm in diameter were scored by
microscopic examination.
www.impactjournals.com/oncotarget

Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was extracted using Trizol (Invitrogen),
and cDNA was synthesized by using TaqMan® microRNA
reverse transcriptase kit (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer recommendations.
Expression of miR-21-microRNA was determined by
the TaqMan miRNA-assay (Applied Biosystems, Foster
City, CA, USA), and normalized using the 2−ΔΔCT -method
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relative to U6-snRNA. All TaqMan-PCR reactions were
performed in triplicates using a Bio-Rad’s MyiQTM singlecolor real-time PCR detection system.

Human lung adenocarcinoma tissue (stage IA or
IIA) was provided from the Biospecimen and Tissue
Procurement Shared Resource Facility of the University
of Kentucky Markey Cancer Center. Lung tissues were
freshly frozen and fixed with 10% formalin for real-time
PCR and immunofluorescence analysis, respectively.

University of Kentucky. Cells (2 × 106 cells per mouse)
from different treatments were resuspended in serum-free
medium with matrigel basement membrane matrix (BD
Biosciences) at a 1:1 ratio (total volume = 100 μl) and
subcutaneously injected into the flanks of nude mice.
Mice were checked daily for tumor appearance, and tumor
volume was measured every 3 days for 30 days. Tumor
volume was determined by Vernier caliper, following the
formula of A × B2 × 0.52, where A is the longest diameter
of tumor and B is the shortest diameter. At the end of the
experiment, mice were sacrificed, the tumors excised and
snap frozen.

Western blot analyses

Immunohistochemical staining

Cells lysates were prepared in ice-cold RIPA buffer
(Sigma-Aldrich) containing freshly added protease
inhibitor cocktail. The lysate was then centrifuged at
12000 g for 10 min at 4°C and the supernatant (total cell
lysate) was collected, aliquoted and stored at −80°C. The
protein concentration was determined using Coomassie
Protein Assay Reagent (Thermo, Rockford, IL). About
40 μg cellular proteins were separated using 6%–12%
SDS-polyacrylamide gel and transferred to nitrocellulose
membrane (Bio-Rad, Hercules, CA). Membranes were
blocked with 5% fat-free dry milk in 1X Tris-buffered
saline (TBS) and incubated with antibodies. Protein bands
were detected by incubating with horseradish peroxidaseconjugated antibodies (Kirkegaard and Perry Laboratories,
Gaithersburg, MD) and visualized with enhanced
chemiluminescence reagent (Perkin Elmer, Boston, MA).
Tumor tissues were homogenized with MagNA Lyser
Green Beads using MagNA Lyser Instrument (Roche,
Indianapolis, IN) and Western blot analysis performed.

Five-μm thick frozen tumor sections were hydrated
in phosphate buffered saline (PBS), and non-specific
binding sites were blocked with 10% horse serum in
PBS. Staining was performed using Vectastain ABC
Kit according to the manufacturer’s protocol (Vector
Laboratories, Burlingame, CA). Briefly, the sections
were incubated with rabbit anti-PDCD4 (1:100) antibody
for 2 h at room temperature, washed and then incubated
with biotinylated secondary antibody for 45 min followed
by incubation with ABC reagent. After washing in PBS,
color was developed with DAB solution until the desired
staining intensity was achieved. Finally, the sections were
counterstained with hematoxylin.

Human tissue samples

Immunofluorescence analysis
BEAS-2B cells or BEAS-2B cells chronically
exposed to Cr(VI) were grown on coverslips in 6-well
plates and treated with Cr(VI). The cells were fixed in
4% paraformaldehyde followed by permeabilization
with 0.2% Triton X-100, blocked with 10% horse serum
in PBS solution, and incubation with antibodies PDCD4
(1:500), E-cadherin (1:100), β-Catenin (1:100), TCF4
(1:100) in buffer A (1% BSA, 0.1% Triton X-100, 10%
horse serum in PBS solution) for 1 h at 37°C. The cells
were then incubated with Alexa Fluor 594 goat anti-rabbit
or Alexa Fluor 488 goat anti-rabbit secondary antibody
and mounted using DAPI. The cells were visualized using
digital confocal microscopy (Confocal Fluorescence
Imaging Microscope, Leica TCS-SP5) or Olympus BX53
fluorescence microscope.
For the formalin-fixed lung tissue fluorescence
immunohistochemical analysis, air-dried tissue sections
were rinsed, blocked, and incubated with primary
antibody overnight. Second antibody was added for
1 h. 300 μl of the diluted DAPI solution was added and
incubated 2–5 min at room temperature. DAPI binds
to DNA and is a convenient nuclear counterstain. The
sections were mounted with an anti-fade mounting media.
Olympus BX53 fluorescence microscope was used for
visualization.

Chronic exposure of animals to Cr(VI) particle
6–8 weeks old, female BALB/c mice were
purchased from Jackson Laboratory (Bar Harbor, MN).
Endotoxin-free basic zinc chromate particle was crushed
using mortar and pestle and then washed with distill water
and acetone to generate a particle of 4.7 μm and a purity of
99–100%. Cr(VI) particle was suspended in sterile 0.9%
sodium chloride solution at a concentration of 1.2 mg/ml
and prepared as previously described [58]. Animals under
a light anesthesia (isoflurane) were intranasally exposed
to a 50 μl dose of chromate or saline once a week up to
12 weeks. Lungs of animals were isolated and subject to
freshly frozen and 10% formalin fixation for real time
PCR and immunohistochemistry analysis, respectively.

Tumorigenesis studies
Athymic nude mice (NU/NU, 6–8 weeks old;
Charles River) were housed in a pathogen-free room
in the animal facilities at the Chandler Medical Center,
www.impactjournals.com/oncotarget
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Statistical analysis

9. Venturutti L, Romero L, Urtreger A, Chervo M, Russo RC,
Mercogliano M, Inurrigarro G, Pereyra M, Proietti C,
Izzo F. Stat3 regulates ErbB-2 expression and co-opts ErbB2 nuclear function to induce miR-21 expression, PDCD4
downregulation and breast cancer metastasis. Oncogene.
2016; 35:2208–22.

Presented values are means ± SD. One-way analysis
of variance (ANOVA) was used for statistical analysis,
with p < 0.05 was considered significantly different.
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